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Abstract
Background: With the development of computed tomography (CT) technology, coronary CT angiography can be
acquired with low doses of radiation and contrast agent without a loss of diagnostic performance. The primary
objective of the CONCENTRATE study is to prove the noninferiority of the enhancement effect of low-concentration
contrast agents compared to a high-concentration contrast agent of the coronary artery and myocardium with
coronary CT angiography.
Methods/Design: The CONCENTRATE study is a prospective, multicenter, noninferiority, randomized trial evaluating
the enhancement effect of low-concentration contrast agents (270 and 320 mg iodine/ml) compared with a high-
concentration contrast agent (370 mg iodine/ml) in the coronary artery and myocardium of coronary artery CT
angiography. The primary efficacy measurement is the enhancement of coronary arteries as measured in Hounsfield
units. The target population comprises 318 patients with suspected coronary artery disease who have been referred
for clinically indicated nonemergent coronary CT angiography. Eligible participants are randomized for three
different concentrations of the contrast agent in a 1:1:1 allocation ratio to one of three arms. The CONCENTRATE
trial is a double-blind study, where the subjects and the outcome assessor are blinded to the concentration of the
contrast agent used for coronary the CT angiography. Eight clinical sites in Korea are participating in this trial.
Discussion: The CONCENTRATE study will determine whether low-concentration contrast agents are able to
provide diagnostic image quality in coronary CT angiography.
Trial registration: NCT02549794. Registered on 14 September 2015.
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Background
Due to developments in computed tomography (CT)
technology, cardiac CT has become very useful as a non-
invasive examination technique in the diagnosis of
obstructive coronary artery disease (CAD), and the ac-
curacy has increased to more than 90 % [1–5]. Specific-
ally, cardiac CT plays a gatekeeper role in reducing
invasive cardiac angiography implemented solely for the
purpose of diagnosis [6]. However, cardiac CT also has
disadvantages, particularly the exposure of patients to
radiation and iodine contrast agent. Consequently, con-
siderable effort has been devoted to identifying ways to
reduce the radiation exposure and the amount of con-
trast agent used. A recently introduced method uses a
combination of a scan with a low tube-based potential
and iterative image reconstruction to reduce both the ra-
diation dose and the amount of contrast agent used for
coronary CT angiography [7]. According to recent stud-
ies of values from this combined method, the signal-to-
noise ratio (SNR) and contrast-to-noise ratio (CNR),
which represent image quality, are higher compared to
the standard method [8, 9]. The standard method uti-
lizes a scan with higher tube potential according to pa-
tient body mass index (BMI) and image reconstruction
by makeshift filtered-back projection under conditions
using the same amount of contrast agent. Therefore, the
amount of contrast agent can be reduced while achiev-
ing the same contrast effect due to the advantage of the
increased effect of contrast enhancement provided by
the low tube potential. Therefore, efficacy studies using
low-concentration contrast agents along with low tube
potential are being performed [10].
The CONCENTRATE study intends to prove that,
compared to the combined method using the makeshift
filtered-back projection image reconstruction and stand-
ard image acquisition according to BMI and with a
standard high-concentration contrast agent, the image
quality does not deteriorate as a result of the combin-
ation of a scan with low tube potential and the iterative
image reconstruction method with low-concentration
contrast agents.
Study objectives
Primary objective
The primary objective of the CONCENTRATE study is
to determine the noninferiority of the contrast enhance-
ment of cardiac CT with low-concentration contrast
agents compared to that with high-concentration con-
trast agent.
Secondary objective
The secondary objective of the CONCENTRATE study is
to determine the diagnostic accuracy of coronary CT angi-
ography in the identification of anatomically obstructive
CAD with low-concentration contrast agent compared
with invasive coronary angiography (ICA) as the reference
standard and to compare it to the accuracy achieved with
a high-concentration contrast agent.
Primary hypothesis
We hypothesized that the use of low-concentration con-
trast agent for coronary CT angiography and myocardial
perfusion would not be inferior to the use of a high-
concentration contrast agent in the enhancement effect
in the coronary artery and in the myocardium.
Methods/Design
Trial design
The CONCENTRATE study is a prospective, multicen-
ter, noninferiority, randomized trial evaluating the en-
hancement effect of low-concentration contrast agents
consisting of 270 and 320 mg iodine/ml (mgI/ml), com-
pared with a high-concentration contrast agent that
contains 370 mgI/ml in the coronary artery and myocar-
dium in coronary artery CT angiography. The target
population includes patients with suspected CAD who
have been referred for clinically indicated nonemergent
ICA. Eligible participants are randomized for three dif-
ferent contrast agent concentrations in a 1:1:1 allocation
ratio to one of three arms of the trial. The CONCEN-
TRATE trial is a double-blind study, where the subjects
and the outcome assessor are blinded to the concentra-
tion of the contrast agent used for coronary CT angiog-
raphy. Eight clinical sites in Korea are participating in
this trial. Every clinical site requires the approval of the
site’s Institutional Review Board. The study protocol and
the informed consent form should be approved by the
Institutional Review Board at each participating site. A
list of the Institutional Review Boards and the status of
their respective approvals are provided in an additional
file (see Additional file 1). Standard protocol items and
organizational structures are provided as additional
files (see Additional files 2 and 3, respectively). A
flow chart of the study is provided in Fig. 1. The in-
formed consent will be obtained from all participants
(see Additional file 4).
Participants
Suitable participants include patients ≥ 20 years of age
who have requested coronary CT angiography to assess
clinical disease. The exclusion criteria include the fol-
lowing: 1) subjects suspected of having myocardial in-
farction, unstable angina pectoris, or coronary artery
disease; 2) subjects with heart attack within 40 days
prior to the CT scan; 3) subjects with a diagnosed com-
plicated heart anomaly; 4) BMI > 35 kg/m2; 5) serum
creatinine ≥ 1.5 mg/dl of renal insufficiency; 6) pregnant
subjects; 6) subjects with a history of hypersensitivity
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reactions to contrast agents; 7) subjects with contraindi-
cations to the use of nitroglycerine; 8) subjects who plan
to participate or enroll in other randomized clinical trials
for cardiovascular disease; or 9) subjects with contraindi-
cations to the use of adenosine (e.g., bronchial asthma,
2–3 degree atrioventricular block, sick sinus syndrome,
systolic blood pressure (SBP) less than 90 mmHg, recent
prescribed history of dipyridamole, or hypersensitivity to
adenosine) (Table 1). Patients who meet the selection
criteria are registered by acquiring informed consent at
the time an examination is ordered and during out-
patient treatment by the investigators. Time schedule,
interventions, assessments, and visits for participants are
provided in a table (Table 2).
Randomization
All enrolled subjects are randomly assigned to one of
three concentrations of contrast agent in a 1:1:1 ratio
based on each trial site. We use concealed allocation
and an adequate computer-generated allocation se-
quence to avoid selection bias. Thus, neither the pa-
tient nor the outcome assessor knows to which group
the patient is allocated. Therefore, if unblinding is
deemed necessary, any of the investigators, coordina-
tors, or CT operators can provide the information of
the contrast agent used. If the assessors of the
outcome learn this information, they should report
this on the corresponding case report form.
Interventions
Three different concentrations of contrast agent are ran-
domly assigned to patients undergoing CT coronary
angiography. A high tube potential is used for CT scans
Fig. 1 CONCENTRATE study workflow. CT, computed tomography; CAD, coronary artery disease
Table 1 Inclusion and exclusion criteria
Inclusion criteria
• Adults at least 20 years old
• Subject who requested a coronary CT angiography to assess clinical
disease
Exclusion criteria
• Subjects suspected of having myocardial infarction, unstable angina
pectoris, or coronary artery disease
• Subjects who experienced heart attack within 40 days prior to the
CT scan
• Subjects with a diagnosed complicated heart anomaly
• BMI > 35 kg/m2
• Serum creatinine ≥ 1.5 mg/dl
• Pregnant subjects
• Subjects with a history of hypersensitivity reaction to contrast agents
• Subjects with contraindications to the use of nitroglycerine
• Subjects who plan to participate or enroll in other randomized
clinical trials for cardiovascular disease.
• Subjects with contraindications to the use of adenosine (e.g., bronchial
asthma, 2–3 degree AV block, sick sinus syndrome, SBP less than
90 mmHg, recent prescribed history of dipyridamole, or hypersensitivity
to adenosine)
CT computed tomography, BMI body mass index, SBP systolic blood pressure
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with the high-concentration contrast agent (370 mgI/
ml), whereas a tube potential that is 20 kVp lower is
used with the low-concentration contrast agents (270
mgI/ml and 320 mgI/ml).
Preparation of patients
If participants do not have contraindications for the use
of the nitroglycerine, they receive sublingual nitroglycer-
ine before coronary CT angiography. If a participant’s
heart rate is equal to or greater than 60 beats per min, a
beta-blocker is administered. If > 50 % stenosis is appar-
ent on the coronary CT angiography, participants will
undergo stress perfusion CT. In these cases, nitroglycer-
ine and beta-blockers are not used. Separate intravenous
lines are secured for the injection of adenosine and con-
trast media.
Contrast agents
Three contrast agents with different iodine concentra-
tions (Visipaque 270, iodixanol 270 mgI/ml; GE Health-
care, Giles St Chalfont, United Kingdom vs. Visipaque
320, iodixanol 320 mgI/ml; GE Healthcare, Giles St
Chalfont, United Kingdom vs. Pamiray 370, iopamidol
370 mgI/ml; Dongkook Pharma, Seoul, Korea) will be
compared in this study. The participants are randomly
assigned to different contrast agents in the same propor-
tions. All contrast agents will be maintained by the same
storage process, based on hospital systems, as used in
general CT examinations. Each contrast agent will be
administered via the antecubital vein of patients in the
same triphasic injection. In the first phase, a 50-ml bolus
of contrast agent will be injected at 5 ml/s. Then, 50 ml
of mixed saline with 30 ml iodine and 20 ml saline will
be injected into patients at 5 ml/s, followed by 40 ml of
saline chaser. The total injected volume of the contrast
agent is 80 ml.
Coronary CT protocol
All coronary CTA studies are acquired with a multide-
tector CT scanner (Discovery HD 750; Gemstone Spec-
tral Imaging, GE Healthcare, Milwaukee, WI, USA).
During scanning, participants hold their breath and are
still. To obtain better image quality for each contrast
agent, scans are performed with different protocols de-
pending on whether high- or low- concentration con-
trast agents are used. If a high-concentration contrast
agent (iopamidol 370 mgI/ml) is used, scans are con-
ducted at 120 kVp for higher BMI (27 < BMI < 35) pa-
tients and at 100 kVp for lower BMI (15 < BMI ≤ 27)
patients, with adjusted mAs (BMI-based tube potential
selection). If a low-concentration contrast agent (iodixa-
nol 270 mgI/ml or iodixanol 320 mgI/ml) is used, scans
are conducted 20 kVp lower than in the BMI-based tube
potential protocol: that is, at 100 kVp for higher BMI
and 80 kVp for lower BMI. A beta-blocker is used for
patients with a heart rate higher than 60 beats per mi-
nute. Scans initiate a bolus tracking method with a 4.8-s
delay after reaching 100 Hounsfield units (HU) in the as-
cending aorta enhancement.
Myocardial perfusion CT
Stress myocardial perfusion CT will be performed in pa-
tients with at least one segment of greater than 50 %
stenosis on coronary CT angiography. A static CT perfu-
sion protocol will be used, and stress will be induced by
infusing 140 mcg/kg/min adenosine under ECG moni-
toring for up to 6 min. The randomly assigned contrast
agent, which was used for coronary CT angiography in
Table 2 Schedule of forms and procedures
Baseline CT angiography CT perfusion Coronary angiography Study
evaluationVisit 1 Visit 2 Visit 3 Visit 4
Screening x
Demographic x
Medical history x
Randomization x
Vital signs x
Laboratory test x
Vital signs 2 x
CT angiography x
Vital signs 3 x
CT perfusion x
Coronary angiography x
Study evaluation x
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the patient, will be injected 4 min 30 s after the adeno-
sine injection, using the same injection method for con-
trast agent and image acquisition settings as used for the
coronary CT angiography with the only difference being
an additional scan delay of 2 s.
Image reconstruction
All images will be reconstructed using an iterative recon-
struction algorithm at 50 % adaptive statistical iterative re-
construction (ASIR, GE Healthcare, Waukesha, Wis, USA).
Evaluation of radiation dose
The dose-length product (DLP) from each shooting will be
collected. The effective radiation dose (mSv) will be calcu-
lated using a conversion factor of 0.014 mSv mGy-1 cm-1.
Retention
This study does not follow the participants’ outcome.
Therefore, no specific plan has been developed to pro-
mote participant retention.
Efficacy analysis
Primary efficacy analysis
The primary efficacy measurement is the HU value of
the coronary arterial lumen acquired from the compari-
son of the image quality from the three different proto-
cols of contrast media in coronary CT angiography.
The coronary artery is divided into 17 segments ac-
cording to the modified American Heart Association
(AHA) classification, and luminal enhancement is
measured for each segment with avoidance of the bor-
derline between the lumen and the vessel wall or epi-
cardial tissue, artifacts, or calcification. Measurement is
performed on three different points in each segment
and the average value is used for the HU value of each
segment. The mean HU value of left main artery and
proximal right coronary artery will be compared be-
tween the different arms of the trial.
Secondary efficacy analysis
Qualitative evaluation of the image quality of the coron-
ary artery will be performed. Two experienced observers
will review all coronary CT images and score the image
quality for each segment with a 4-point grading system
on visual assessment: Grade 1, nondiagnostic; Grade 2,
reduced image quality; Grade 3, nonlimiting artifacts;
and Grade 4, complete absence of motion artifacts with
good attenuation of the vessel lumen and clear delinea-
tion of the vessel walls with the additional ability to as-
sess luminal stenosis.
Quantitative evaluation of image quality of perfusion
CT will be performed. The myocardium will be divided
into 16 segments according to AHA classification, and
the HU value of each segment will be measured. Mean
HU value, SNR, and CNR of myocardial enhancement
will be compared between the different arms of the trial.
Diagnostic accuracy of coronary CT angiography com-
pared to invasive coronary angiography will be calcu-
lated. Segment-basis analysis, sensitivity, specificity,
positive predictive value, negative predictive value, and
accuracy of CT angiography for diagnosis of the pres-
ence of CAD defined by more than 50 % diameter sten-
osis compared to invasive coronary angiography will be
calculated and compared between the different concen-
trations of contrast agent by means of a generalized esti-
mating equation based on a binary logistic model.
Quantitative evaluation of image quality of coronary
artery will be performed on a per-vessel and per-
segment basis.
Statistical methods
Sample size and power calculation
The noninferiority margin was justified by an indirect
confidence interval approach using the point estimate
because the constancy assumption was not applicable in
this trial. In a previous study [11], the reduction rate be-
tween iopamidol 370 mgI/ml and iodixanol 320 mgI/ml
was 18 % (from 439.96 to 362.06 HU), and we assumed
that the HU value between the low-concentration and
high-concentration groups would be the same. Conse-
quently, we estimate 9 % (0.5 × (18 % - 0 %)) of the re-
ported mean HU [10] to be the noninferiority margin,
allowing a loss of less than 50 % of the active control ef-
fect, which corresponds to a noninferiority margin of
51.26 HU [12]. Clinically, 250–300 HU is considered
sufficient enhancement for coronary angiography [13].
Therefore, a reduction of 51.26 HU from 439.96 HU,
which results in 388.7 HU, is clinically acceptable. For
the mean contrast enhancement as an attenuation value
of CT (HU) in the noninferiority test, we assumed same
mean HU among the three groups and a standard devi-
ation of 118.93 for the HU based on a previous study
[10]. With these assumptions and a 10 % dropout rate,
106 subjects per group are needed to obtain 80 %
statistical power with a corrected two-sided α ≒
0.0167 (=0.05/3).
Primary statistical analysis
Per-protocol analysis will be performed primarily; an
additional intention-to-treat analysis will be also per-
formed. The 98.33 % confidence interval (CI) for the dif-
ference of mean contrast enhancement in the ROIs will
be calculated. The noninferiority of the low-dose group
compared to the high-dose group will be demonstrated
if the lower bound of the two-sided 98.33 % CI lies
above the pre-specified noninferiority margin. Because
missing values are expected for 5 % or fewer of the par-
ticipants, we have planned complete-case analysis for
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the primary analysis. To account for multiple observa-
tions per patient in secondary analysis, we will use a lin-
ear mixed model, including fixed effects for the group
and random intercepts for the patient. Patients with a
missing observation in some vessel or segment will be
included in the per-vessel and per-segment analysis by
using the linear mixed model. Analysis of covariance
(ANCOVA) with BMI as a covariate will be used to
compare the mean HU of the myocardium on static per-
fusion CT. Inter-reader agreement for the assessment of
image quality will be evaluated using a linearly weighted
kappa statistic. Analysis of variance (ANOVA) will be
used to compare mean changes in heart rate before and
after CT examinations among the three groups. To com-
pare the diagnostic accuracy of invasive coronary angi-
ography for diagnosis of significant coronary artery
stenosis with more than 50 % stenosis among the three
groups, logistic regression analysis using a generalized
estimating equation (GEE) will be used to account for
the correlation among multiple segments within the
same subject. All statistical analyses will be performed
using SAS (SAS Ver. 9.2; SAS Institute, Cary, NC, USA)
and two-sided P values less than 0.05 will be considered
statistically significant.
Data management
The data-coordinating center in Severance Hospital is
collecting data through a secure Internet connection to
the central server and monitoring the overall dataset. At
the start of the trial, the monitors conducted a tutorial
on the web-based data entry system and the image up-
load system. They will audit the overall quality and in-
tegrity of the data regularly every 6 months and, if
necessary, contact the site investigator and coordinator
to review and confirm the correctness of the data with
source data in compliance with the protocol. The moni-
tors will verify that all adverse events were documented
in the correct format and are consistent with protocol
definition. The monitor conducts the monitoring pro-
cedure independently from the investigators and the
sponsor. The primary and secondary endpoints in this
trial include only the image quality and not the patients’
clinical outcomes. If the quality is not enough to deter-
mine significant coronary artery disease due to insuffi-
cient enhancement from a low-concentration contrast
agent, repeat examination with a high-concentration
contrast agent can be used at the site investigator’s dis-
cretion. Therefore, the conduct of an interim analysis is
not needed to evaluate any potentially important reasons
to modify or discontinue the trial. Adverse effects and
serious adverse events will be recorded in the case re-
port form. A summary of adverse effects and serious
adverse effects will be immediately forwarded the
independent Institutional Review Board and local health
authorities, according to local regulations.
Discussion
The CONCENTRATE study is a prospective, multicen-
ter, noninferiority, randomized trial evaluating the en-
hancement effect of two low-concentration contrast
agents compared with the high-concentration contrast
agent recommended for sufficient opacification in
coronary CT angiography, according to established
guidelines [14].
The accuracy of coronary CT angiography in the diag-
nosis of coronary artery stenosis is affected by image
quality, which is dependent on the CNR. To achieve a
high CNR, high-concentration contrast agents are
usually recommended and have been widely used in
everyday clinical practice as a standard protocol [14].
According to a study that compared two contrast agents
with different concentrations (400 mgI/ml vs. 320 mgI/
ml), coronary arterial enhancement was higher when the
high-concentration contrast agent was used and higher
enhancement levels were found to be associated with
lower numbers of inadequately visualized segments [11].
However, in another study that compared four different
concentrations (370, 350, 320, and 270 mgI/ml), image
quality grade was higher with low-concentration con-
trast agents, although high-concentration contrast
agents showed greater vascular enhancement [15]. The
fact that heart rate variability was lower with low-
concentration contrast agents, which were all iso-
osmolar agents, whereas the high-concentration contrast
agents were all low-osmolar agents, might partially ac-
count for the higher image quality obtained with lower-
concentration-contrast agents in this study. The lowest
enhancement of 369.1 ± 85.4 HU obtained with the low-
est concentration of 270 mgI/ml in this study could be
considered adequate because adequate intra-arterial en-
hancement for coronary CT angiography has been con-
sidered to require more than 250 HU according to
previous reports [13, 14].
In this regard, an effort to reduce the amount of iodine
should be considered to reduce the probability of
contrast-induced nephropathy in patients at risk, as long
as diagnostic image quality is maintained [16, 17]. When
using low-concentration contrast agents, a combination
of low tube potential and iterative reconstruction would
be helpful for maintaining high vascular enhancement
and image quality. A lower tube potential has the advan-
tages of reducing radiation dose and improving image
contrast. However, using a lower tube potential reduces
X-ray penetration and increases image noise. Iterative
reconstruction is a solution for this problem because it
improves image quality by reducing image noise. The
combination of a lower tube potential and iterative
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image reconstruction does not result in a deterioration
of image quality and diagnostic accuracy [8, 9]. A single
center study tested the feasibility of this combination
with a low-concentration (270 mgI/ml) contrast agent
compared to a high-concentration contrast agent (370 mg
iodine/ml) in coronary CT angiography and demonstrated
that a low-concentration contrast agent maintained the
contrast enhancement without impairing image quality
[10]. The CONCENTRATE trial has been designed to val-
idate this finding as a multicenter study to limit possible
bias and secure maximum generalizability.
The CONCENTRATE study will determine whether
low-concentration contrast agents are able to provide
diagnostic image quality on coronary CT angiography.
Because the CONCENTRATE trial will only measure
the coronary artery lumen and the myocardium in
coronary CT angiography, the results of the CONCEN-
TRATE trial should be further validated for other appli-
cations of cardiac CT, including in the evaluation of
plaque, in-stent restenosis, and image-based fractional
flow reserve. With expanding options for technology,
such as feasibly scanning with 70 kVp, and more sophis-
ticated iterative reconstruction methods, CT protocols
should be further optimized to apply the results of the
CONCENTRATE trial in the real world.
Trial status
Recruitment commenced in July 2015.
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